Bank of America projects a 58% potential gain for Alvotech, citing easing FDA hurdles and a wave of biosimilar launches that could reshape the company's U.S. market prospects.
Alvotech, a biosimilar manufacturer previously affected by regulatory delays and inconsistent commercial performance, is once again in focus on Wall Street. Bank of America has initiated coverage of Alvotech (ALVO) with a Buy rating and a $7 price target, representing a 58% upside from its $4.43 reference price as of August 24. The bank's analysis points to a shift in Alvotech's regulatory position and the potential for several near-term product launches.
Alvotech expects FDA decisions on multiple biosimilar programs in the fourth quarter of 2026, following confirmation of standard review timelines after resubmissions.
Launch Cycle and Market Potential
Bank of America anticipates Alvotech's most substantial launch cycle to date, with upcoming biosimilars for Simponi and standard-dose Eylea, followed by Entyvio. A high-dose Eylea candidate is also in development for later in the decade. The bank highlights Alvotech's focus on provider-administered, buy-and-bill markets, which generally offer more favorable pricing and adoption rates compared to pharmacy-benefit markets such as those for Humira and Stelara.
The recent closure of the FDA inspection at Alvotech's Reykjavik facility is especially significant, as the company has historically faced regulatory delays and inconsistent commercial results. With the regulatory risk now reduced, analysts see this as the beginning of the most important launch cycle in Alvotech's history, particularly for biosimilars targeting Simponi, standard-dose Eylea, and later Entyvio.
Partnerships and Execution Risks
Alvotech continues to expand through partnerships rather than building a large in-house commercial team. On August 21, it announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilars to Imfinzi and Hemlibra in the U.S. and select Asian markets. This approach enables broader reach without significant overhead, but also increases reliance on partner execution and market uptake.
Bank of America identifies several risks: slower commercial adoption, pricing pressure, manufacturing or regulatory setbacks, and intellectual property disputes could all affect launch timing and profitability. The standard-dose Eylea market is already competitive, and future opportunities in Entyvio and high-dose Eylea depend in part on ongoing patent litigation. As regulatory barriers decrease, Alvotech's commercial execution will be the primary factor influencing shareholder value.
Regulatory and Market Context
Biosimilars are approved in the U.S. through an abbreviated FDA pathway, provided they demonstrate high similarity to reference biologics and no clinically meaningful differences in safety or efficacy. This process is intended to reduce development costs and timelines while maintaining rigorous standards. For investors, the timing of FDA decisions and the competitive landscape for each biosimilar are key considerations in evaluating potential returns.
Alvotech's trajectory reflects the broader challenges facing biosimilar developers, including regulatory delays, manufacturing investments, and evolving market dynamics. As Bank of America's analysis indicates, the company's years of platform investment may soon yield results if it can execute commercially. For context, the S&P 500 Biotechnology Select Industry Index declined 2.1% for the week ending August 23, highlighting sector volatility as investors respond to regulatory news, earnings, and competition for new therapies.
Biosimilars represent a growing segment of the U.S. pharmaceutical market, offering lower-cost alternatives to branded biologics after patent expiration. While the abbreviated approval pathway is designed to foster competition and reduce healthcare costs, success depends on navigating complex patent issues, scaling manufacturing, and securing payer acceptance. Investors should closely monitor regulatory progress, commercial execution, and market adoption when evaluating opportunities in this sector.
